192 related articles for article (PubMed ID: 24333643)
1. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.
Krátký M; Vinšová J; Novotná E; Stolaříková J
Eur J Pharm Sci; 2014 Mar; 53():1-9. PubMed ID: 24333643
[TBL] [Abstract][Full Text] [Related]
2. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase.
Krátký M; Vinšová J; Novotná E; Mandíková J; Wsól V; Trejtnar F; Ulmann V; Stolaříková J; Fernandes S; Bhat S; Liu JO
Tuberculosis (Edinb); 2012 Sep; 92(5):434-9. PubMed ID: 22765970
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity of salicylanilide 4-(trifluoromethyl)-benzoates.
Krátký M; Vinšová J; Novotná E; Mandíková J; Trejtnar F; Stolaková J
Molecules; 2013 Mar; 18(4):3674-88. PubMed ID: 23529028
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
Krátký M; Volková M; Novotná E; Trejtnar F; Stolaříková J; Vinšová J
Bioorg Med Chem; 2014 Aug; 22(15):4073-82. PubMed ID: 24953953
[TBL] [Abstract][Full Text] [Related]
5. Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.
Baranyai Z; Krátký M; Vinšová J; Szabó N; Senoner Z; Horváti K; Stolaříková J; Dávid S; Bősze S
Eur J Med Chem; 2015 Aug; 101():692-704. PubMed ID: 26210507
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
Krátký M; Bősze S; Baranyai Z; Szabó I; Stolaříková J; Paraskevopoulos G; Vinšová J
Bioorg Med Chem; 2015 Feb; 23(4):868-75. PubMed ID: 25593095
[TBL] [Abstract][Full Text] [Related]
7. Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
Krátký M; Janďourek O; Baranyai Z; Novotná E; Stolaříková J; Bősze S; Vinšová J
Eur J Med Chem; 2019 Nov; 181():111578. PubMed ID: 31401536
[TBL] [Abstract][Full Text] [Related]
8. Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains.
Krátký M; Vinšová J; Stolaříková J
Molecules; 2012 Oct; 17(11):12812-20. PubMed ID: 23114617
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
Kozic J; Novotná E; Volková M; Stolaříková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2012 Oct; 56():387-95. PubMed ID: 22907036
[TBL] [Abstract][Full Text] [Related]
10. Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.
Vinšová J; Kozic J; Krátký M; Stolaříková J; Mandíková J; Trejtnar F; Buchta V
Bioorg Med Chem; 2014 Jan; 22(2):728-37. PubMed ID: 24369840
[TBL] [Abstract][Full Text] [Related]
11. Antimycobacterial activity of salicylanilide benzenesulfonates.
Krátký M; Vinšová J; Rodriguez NG; Stolaříková J
Molecules; 2012 Jan; 17(1):492-503. PubMed ID: 22222908
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
13. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
14. Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.
Férriz JM; Vávrová K; Kunc F; Imramovský A; Stolaríková J; Vavríková E; Vinsová J
Bioorg Med Chem; 2010 Feb; 18(3):1054-61. PubMed ID: 20060303
[TBL] [Abstract][Full Text] [Related]
15. New amino acid esters of salicylanilides active against MDR-TB and other microbes.
Krátký M; Vinšová J; Buchta V; Horvati K; Bösze S; Stolaříková J
Eur J Med Chem; 2010 Dec; 45(12):6106-13. PubMed ID: 20937542
[TBL] [Abstract][Full Text] [Related]
16. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
17. Salicylanilide diethyl phosphates as potential inhibitors of some mycobacterial enzymes.
Krátký M; Novotná E; Saxena S; Yogeeswari P; Sriram D; Švarcová M; Vinšová J
ScientificWorldJournal; 2014; 2014():703053. PubMed ID: 25538961
[TBL] [Abstract][Full Text] [Related]
18. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
20. Salicylanilide esters of N-protected amino acids as novel antimicrobial agents.
Imramovský A; Vinsová J; Férriz JM; Buchta V; Jampílek J
Bioorg Med Chem Lett; 2009 Jan; 19(2):348-51. PubMed ID: 19081718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
